Abbott Hits Sandoz With New Niaspan Patent Suit
Abbott Laboratories has launched another patent infringement suit against Sandoz Inc. in an effort to keep a generic version of blockbuster cholesterol drug Niaspan off the market....To view the full article, register now.
Already a subscriber? Click here to view full article